Exploring maternal immune activation, placental defense mechanisms, neuroinflammation, microglial development, and the relationship between prenatal immune conditions and neurological development.
Introduction: The Immune System and the Developing Brain
The developing brain is influenced by far more than the genetic instructions that guide its formation. From the earliest stages of pregnancy, neurological development occurs within a complex physiological environment shaped by maternal metabolism, placental function, endocrine signaling, immune regulation, and the continuous exchange of biological information between mother and fetus.
Among these influences, the immune system has emerged as an important area of developmental neuroscience.
Traditionally, immunity has been understood primarily as a defense system responsible for identifying pathogens, responding to infection, and supporting tissue repair. However, advances in neuroimmunology have revealed that immune-related cells and signaling molecules also participate in normal nervous system development.
Microglia contribute to neural tissue maintenance and aspects of synaptic remodeling. Complement proteins participate in certain processes involved in circuit refinement. Cytokines influence cellular communication, while immune interactions at the maternal–fetal interface help establish the conditions necessary for pregnancy.
These discoveries raise important questions. Can inflammatory signaling during pregnancy influence fetal neural development? Do maternal metabolic or autoimmune conditions modify the prenatal immune environment? How might the timing and intensity of an immune response influence developmental outcomes? And what can these findings actually tell us about autism, ADHD, Tourette syndrome, schizophrenia, and other neurological conditions?
Four of the supplied research papers examine these questions in detail.
Knuesel and colleagues, writing in Nature Reviews Neurology in 2014, explored maternal immune activation as a possible contributor to neurological and psychiatric conditions.
Han and colleagues expanded this work through a 2021 systematic review in Translational Psychiatry, followed by a comprehensive Nature Reviews Neurology article examining neuroinflammation and neurodevelopmental disorders.
More recently, Alippe and colleagues reviewed innate immune responses at the maternal–fetal interface, providing a detailed account of how placental and maternal immune systems respond to infection.
Together, these studies illustrate both the promise and limitations of contemporary neuroimmune research.
Immune signaling is an essential component of normal neurological development, but establishing whether a particular immune disturbance causes a human neurodevelopmental condition requires substantially more evidence than demonstrating inflammation or an association with a diagnosis.
Pregnancy Is Not a State of Generalized Immune Suppression
One persistent misconception is that pregnancy requires the maternal immune system to become broadly suppressed so that the developing fetus is not rejected.
Pregnancy does involve specialized mechanisms of immune tolerance. However, maternal immunity must also remain capable of responding to pathogens and maintaining tissue integrity.
The immune system undergoes dynamic changes throughout pregnancy, and different immune functions become more or less prominent depending on tissue, gestational stage, and physiological context.
At the maternal–fetal interface, maternal immune cells interact with fetal-derived placental tissues.
These interactions contribute to implantation, vascular remodeling, placental development, and protection against infectious agents.
In their 2025 review, Alippe and colleagues describe how innate immune signaling pathways coordinate host defense while maintaining the specialized physiological conditions of gestation.
The objective is not the elimination of immune activity, but its appropriate regulation.
The Placenta as an Immunological Interface
The placenta is commonly described as an organ responsible for nutrient and gas exchange between maternal and fetal circulations.
However, its functions are considerably broader.
Placental tissues participate in endocrine signaling, metabolic regulation, nutrient transport, and immune defense.
The maternal–fetal interface includes the maternally derived decidua and fetal-derived placental tissues.
Within these compartments, immune and nonimmune cells communicate through a variety of molecular pathways.
Syncytiotrophoblasts form an important protective barrier between maternal blood and fetal tissues.
Trophoblast cells can also participate directly in innate immune responses.
Maternal decidual natural killer cells contribute to reproductive tissue regulation and vascular development.
Macrophages, regulatory T cells, and other immune populations participate in local immune communication.
The placenta therefore functions not simply as a passive filter, but as an active biological interface.
Importantly, placental anatomy and immune organization change throughout pregnancy.
The biological consequences of an immune challenge may therefore depend partly on when it occurs.
Innate Immune Recognition: How the Placenta Detects Potential Threats
The innate immune system recognizes conserved molecular features associated with pathogens and tissue damage.
These signals are commonly described as pathogen-associated molecular patterns and damage-associated molecular patterns.
Pattern-recognition receptors detect these signals and initiate cellular responses.
Toll-like receptors are among the best-characterized receptor families involved in this process.
Other pathways include RIG-I-like receptors, cytosolic nucleic-acid sensors, and inflammasome-related mechanisms.
Activation can stimulate production of interferons, cytokines, chemokines, and other signaling molecules.
These responses may help control infection and limit pathogen transmission.
However, excessive or poorly regulated inflammatory signaling can interfere with placental function.
Alippe and colleagues emphasize that the consequences of immune activation depend on the pathogen, cell type, tissue compartment, and gestational stage.
This illustrates why inflammation cannot be treated as one uniform biological state.
Maternal Immune Activation: What Does the Term Mean?
Maternal immune activation, commonly abbreviated MIA, describes immune responses occurring during pregnancy that may influence the intrauterine environment.
Early research focused heavily on infections.
Experimental models have used viral infection, bacterial components, or synthetic immune stimulants to investigate how maternal inflammation might affect offspring development.
However, contemporary research also considers chronic inflammatory states associated with certain maternal medical conditions.
These include obesity, diabetes, autoimmune disease, asthma, and hypertensive disorders of pregnancy.
The central hypothesis is that immune signaling may influence placental processes, fetal physiology, or subsequent neurological development.
Importantly, maternal immune activation is a research construct rather than a single clinical diagnosis.
It does not have one universally accepted laboratory definition that can be applied to every pregnant patient.
Nor does an elevated inflammatory biomarker establish that fetal brain development has been harmed.
Acute Inflammation and Chronic Low-Grade Inflammation
Inflammation can occur in response to infection, tissue damage, or other physiological challenges.
Acute inflammatory responses typically develop over a relatively short period.
They may involve rapid cytokine production, activation of innate immune cells, and coordinated protective responses.
Chronic low-grade inflammation involves more persistent alterations in inflammatory signaling.
These patterns can occur in some metabolic and immune-mediated conditions.
Han and colleagues' systematic review investigated both acute and chronic maternal inflammatory states in relation to neurodevelopmental outcomes.
Their review identified 32 meta-analyses and 26 additional individual studies examining maternal conditions and offspring neurodevelopmental disorders.
Associations were reported across multiple maternal conditions and developmental diagnoses.
However, the authors emphasized that the human evidence was heterogeneous.
Different studies used different measures of inflammation, different definitions of exposure, and different approaches to controlling confounding.
Consequently, these associations do not establish that all the conditions studied influence neurodevelopment through the same inflammatory mechanism.
Cytokines: Biological Messengers With Multiple Functions
Cytokines are signaling proteins involved in communication among immune and other cell populations.
They participate in inflammation, immune regulation, cellular differentiation, and tissue responses.
Relevant molecules in maternal immune activation research include interleukin-1β, interleukin-6, interleukin-17A, tumor necrosis factor, and several interferons.
However, the effects of these molecules are context-dependent.
A cytokine may support normal protective responses under one set of circumstances while contributing to tissue dysfunction under another.
Its biological activity depends on concentration, receptor expression, cellular environment, timing, and interactions with other pathways.
Research involving animal models has identified several potential mechanisms through which cytokine signaling could alter neurological development.
Nevertheless, these experimental findings do not establish that an isolated maternal cytokine measurement can predict autism, ADHD, or another developmental outcome.
The human clinical utility of cytokine-based screening for these purposes remains unproven.
The IL-6 and IL-17A Pathways
Some of the most influential experimental work on maternal immune activation has investigated interleukin-6 and interleukin-17A.
IL-6 can participate in inflammatory signaling and influence differentiation of certain immune populations.
IL-17A is associated with T-helper-17-related immune responses.
In a 2016 study published in Science, Choi and colleagues demonstrated that maternal IL-17A signaling was required for particular cortical and behavioral changes produced by an experimental maternal immune activation protocol in mice.
The investigators identified abnormal cortical development and alterations in offspring behaviors under those experimental conditions.
These findings provided an important mechanistic advance.
However, the study involved mice subjected to experimentally induced immune activation.
Its results cannot be interpreted as proof that maternal IL-17A causes autism in humans.
Similarly, experimental blockade of an inflammatory pathway does not establish that administering immune-targeting medications during human pregnancy would safely prevent autism.
Such interventions would require extensive clinical evaluation of both maternal and fetal risks.
Microglia and the Development of Neural Circuits
Microglia are specialized immune-related cells that reside in the central nervous system.
They arise from embryonic progenitor populations and become established in neural tissue early in development.
Microglia participate in tissue surveillance, responses to cellular injury, clearance of cellular material, and aspects of neural circuit remodeling.
They also interact with neurons, astrocytes, and other glial populations.
Knuesel and colleagues proposed that maternal immune activation might influence later neurological function partly through alterations in microglial development or responsiveness.
Their review discussed the concept of microglial priming.
This refers to changes in cellular responsiveness that may influence reactions to later challenges.
However, microglial priming is not a single standardized clinical state.
The concept encompasses multiple experimental phenomena.
It should therefore not be treated as an established explanation for all neurodevelopmental disorders.
Synaptic Pruning and Immune Signaling
During development, neural networks undergo substantial remodeling.
Early synapses are formed, strengthened, weakened, or eliminated as neural circuits mature.
Some immune-related pathways participate in these processes.
Complement proteins can help identify certain synaptic structures for removal, while microglia can participate in the elimination of selected synaptic material.
Experimental research suggests that disturbances in these processes may contribute to altered neural connectivity under particular conditions.
However, it is overly simplistic to describe developmental disorders as the result of too much or too little synaptic pruning.
Synaptic remodeling varies across brain regions and developmental periods.
Different neurological conditions also involve different genetic and physiological mechanisms.
At present, clinicians cannot diagnose an individual child's synaptic pruning pattern through a routine clinical test.
Nor can standard rehabilitation techniques be assumed to directly correct a proposed pruning abnormality.
Maternal Metabolic Health and Neurodevelopmental Outcomes
Metabolic conditions are another important component of the maternal immune activation literature.
In 2012, Krakowiak and colleagues published Maternal Metabolic Conditions and Risk for Autism and Other Neurodevelopmental Disorders in Pediatrics.
The study examined 517 children with autism, 172 with developmental delay, and 315 population controls.
Maternal metabolic conditions included diabetes, hypertension, and obesity.
Collectively, these conditions were associated with greater odds of autism and developmental delay.
The adjusted odds ratio was 1.61 for autism and 2.35 for developmental delay.
The investigators also reported differences in certain developmental scores among exposed children.
These observations helped establish maternal metabolic health as an important area of developmental epidemiology.
However, the study was observational.
It did not demonstrate that inflammation directly caused the identified neurodevelopmental differences.
Nor could it fully exclude genetic, socioeconomic, or other confounding influences.
What Newer Research Adds to the Diabetes Question
A large 2026 study by Jo and colleagues examined maternal diabetes and later neuropsychiatric diagnoses using cohorts from South Korea and Japan.
The study included approximately 2.72 million mother–child pairs in its main Korean cohort, with an additional Japanese validation cohort.
Pregestational diabetes was associated with increased risks of several neuropsychiatric outcomes.
For autism, the adjusted hazard ratio was 1.39.
However, gestational diabetes showed only modest associations in conventional analyses.
Sibling-comparison analyses did not identify a meaningful association between gestational diabetes and the studied outcomes.
These findings are important because they suggest that associations involving diabetes depend on the type of diabetes and the research design.
They also demonstrate that shared familial factors may account for some associations.
The findings support effective diabetes management before and during pregnancy but do not establish that diabetes treatment prevents autism.
Maternal Infection and Autism: Why Causal Inference Matters
Several of the supplied reviews discuss associations between maternal infection and autism.
Historically, these associations contributed to the development of the maternal immune activation hypothesis.
However, more recent research has introduced important qualifications.
A 2022 Swedish study published in The Lancet Psychiatry examined 549,967 children.
Maternal infection during pregnancy was associated with later autism diagnoses in conventional analyses.
The hazard ratio was 1.16.
However, when researchers compared siblings within families, the association was no longer evident.
The sibling-comparison hazard ratio was 0.94.
These findings suggest that familial or other shared factors explained much of the original association.
The researchers did not rule out effects from every specific infection.
Certain congenital infections can cause established neurological injury.
Nevertheless, the findings challenge the claim that common maternal infections generally cause autism through immune activation.
This is an important example of scientific progress refining an earlier biological hypothesis.
ADHD, Tourette Syndrome, and Other Neurological Conditions
Han and colleagues also reviewed associations between maternal inflammatory states and ADHD or Tourette syndrome.
Some observational studies identified relationships involving maternal obesity, autoimmune disease, asthma, stress, or other conditions.
However, the strength and consistency of evidence varied substantially.
The reviews also discussed possible relationships between prenatal immune perturbations and schizophrenia, epilepsy, or other neurological conditions.
These hypotheses are biologically interesting because early brain development contributes to neural systems that remain relevant throughout life.
However, autism, ADHD, Tourette syndrome, schizophrenia, and epilepsy are distinct conditions.
They should not be grouped into one disease process merely because they share some genetic, neurological, or inflammatory associations.
A proposed common pathway does not eliminate important differences in their clinical characteristics or mechanisms.
Epigenetic Programming and Developmental Vulnerability
Epigenetic mechanisms regulate aspects of gene expression without changing the underlying DNA sequence.
They include DNA methylation, histone modifications, and regulatory RNA pathways.
Immune signaling can influence epigenetic regulation in some experimental systems.
For this reason, researchers have proposed that certain prenatal inflammatory exposures might produce lasting changes in immune or neural cellular responsiveness.
Han and colleagues discuss the possibility of biological embedding through interactions between environmental exposures, inflammatory signaling, and epigenetic regulation.
However, demonstrating an epigenetic change is not equivalent to proving that it causes a neurological disorder.
Furthermore, some epigenetic differences may arise as consequences of disease processes, medications, or developmental experiences.
Establishing causality requires appropriate experimental and longitudinal research.
What This Means for Clinical Evaluation
The most important clinical implication is that maternal health deserves appropriate attention before and during pregnancy.
Established infections should be prevented or treated according to obstetric guidance.
Diabetes should be appropriately managed.
Autoimmune and inflammatory diseases should receive suitable medical care.
Hypertension and other relevant conditions should be evaluated and treated.
These recommendations are justified by established maternal and fetal health benefits.
They do not require assuming that every maternal condition causes a neurodevelopmental disorder.
For children with neurodevelopmental concerns, immune evaluation should be guided by actual clinical findings.
Recurrent severe infections, unusual inflammatory symptoms, or evidence of autoimmune disease may warrant specialist assessment.
However, routine broad inflammatory panels, cytokine testing, or immune-suppressing treatment are not established approaches to diagnosing or treating autism, ADHD, or Tourette syndrome.
How This Research Informs Our Neurodevelopmental Care
We recognize the immune and nervous systems as interacting components of human physiology.
The growing neuroimmune literature encourages clinicians to understand these relationships while maintaining appropriate standards of evidence.
For families seeking neurodevelopmental assessment, this means considering relevant medical history, neurological findings, functional abilities, and co-occurring health concerns.
It does not mean assuming every developmental difference is caused by inflammation.
Nor does it support treating exploratory immune biomarkers as definitive explanations of a child's neurological presentation.
Our approach emphasizes comprehensive history-taking, appropriate functional assessment, research-informed education, and collaboration with pediatric, neurological, developmental, and immunological specialists when indicated.
The objective is to identify meaningful clinical needs rather than pursue speculative mechanisms without demonstrated treatment benefits.
Conclusion: Neuroimmune Research Is Important, but Clinical Certainty Must Be Earned
Research on maternal immune activation has expanded our understanding of how immunity interacts with developing neural systems.
It has identified important biological pathways involving placental defense, cytokine signaling, microglial development, and gene regulation.
It has also encouraged more comprehensive investigation of maternal health during pregnancy.
However, contemporary research demonstrates why caution is necessary.
Animal experiments establish biological mechanisms under controlled conditions.
Observational studies identify associations.
Sibling comparisons and other causal inference methods help evaluate alternative explanations.
These forms of evidence answer different questions.
A pathway demonstrated in mice should not be presented as a confirmed cause of autism in humans.
An association between maternal obesity and developmental outcomes does not demonstrate that an inflammatory marker mediates that relationship.
And a theoretical opportunity to influence immune signaling does not establish a safe or effective treatment.
The future of neuroimmune research depends on understanding which mechanisms are genuinely causal, which individuals may be affected, and which interventions produce meaningful clinical benefits.
Until those questions are answered, the most responsible approach is to protect maternal health, recognize neurodevelopmental differences accurately, and provide children with evidence-based care tailored to their needs.
Research References
Knuesel I, Chicha L, Britschgi M, et al. Maternal immune activation and abnormal brain development across CNS disorders. Nature Reviews Neurology. 2014;10:643–660. https://doi.org/10.1038/nrneurol.2014.187
Han VX, Patel S, Jones HF, et al. Maternal acute and chronic inflammation in pregnancy is associated with common neurodevelopmental disorders: a systematic review. Translational Psychiatry. 2021;11:71. https://doi.org/10.1038/s41398-021-01198-w
Han VX, Patel S, Jones HF, Dale RC. Maternal immune activation and neuroinflammation in human neurodevelopmental disorders. Nature Reviews Neurology. 2021;17:564–579. https://doi.org/10.1038/s41582-021-00530-8
Alippe Y, Hatterschide J, Coyne CB, Diamond MS. Innate immune responses to pathogens at the maternal–fetal interface. Nature Reviews Immunology. https://doi.org/10.1038/s41577-025-01191-0
Krakowiak P, Walker CK, Bremer AA, et al. Maternal metabolic conditions and risk for autism and other neurodevelopmental disorders. Pediatrics. 2012;129–e1128. https://doi.org/10.1542/peds.2011-2583
Choi GB, Yim YS, Wong H, et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science. 2016;351:933–939. https://doi.org/10.1126/science.aad0314
Brynge M, Sjöqvist H, Gardner RM, et al. Maternal infection during pregnancy and likelihood of autism and intellectual disability in children in Sweden: a negative control and sibling comparison cohort study. The Lancet Psychiatry. 2022;9:782–791. https://doi.org/10.1016/S2215-0366(22)00264-4
Jo H, Yeo D, Lee S, et al. Maternal pregestational and gestational diabetes and neuropsychiatric risk in offspring: a binational cohort study. Diabetes, Obesity and Metabolism. 2026;28:4935–4948. https://doi.org/10.1111/dom.70682